How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?
  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?
  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Marketing authorisation indication

2.1 Autologous anti-CD19-transduced CD3+ cells (Tecartus, Kite) is expected to be indicated for 'the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia'.

2.2 The dosage schedule will be available in the summary of product characteristics for autologous anti-CD19-transduced CD3+ cells.


2.3 The list price for single infusion is £316,118 (excluding VAT, MIMS [Monthly Index of Medical Specialities] online, accessed October 2022).

The company has a commercial arrangement. This makes autologous anti-CD19-transduced CD3+ cells available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.